IPO Issue Details
Issue Price / Price Band₹1,050 per share (Fixed Price)
Face Value₹2 Per Share
Lot Size14 Shares per Lot
Total Issue Size1,28,53,442 shares (aggregating up to ₹1,347.76 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryOffer For Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenTue, 08 Dec 2015
Subscription CloseThu, 10 Dec 2015
Anchor AllotmentMon, 07 Dec 2015
Basis of AllotmentWed, 16 Dec 2015
Initiation of RefundsThu, 17 Dec 2015
Credit of Shares to DematThu, 17 Dec 2015
Listing DateWed, 23 Dec 2015
UPI Mandate Deadline2015-12-10
Application & Investment Details
Retail — Min (1 Lots)₹14,700 — 14 shares
Retail — Max (13 Lots)₹191,100 (13 Lots)
HNI — Min (14 Lots)₹2,05,800 — 196 shares
Pre-IPO Promoter Holding11,95,65,000 shares
Post-IPO Promoter Holding11,95,65,000 shares
About Alkem Laboratories Ltd.
Incorporated in 1973, Alkem Labs is leading India based pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.Alkem Labs produces branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals, which they market in India and 55 countries internationally, primarily the United States.Company's pharmaceutical business is organized into domestic and international operations. Alkem Labs has a portfolio of over 736 brands in India. Company's most significant therapeutic areas in domestic market are anti-infectives, gastro-intestinal, pain and analgesics, and vitamins, minerals and nutrients.Alkem Labs have a total of 16 manufacturing facilities: 14 manufacturing facilities at five locations in India and two in the United States. Company have four research and development facilities, two in India and two in the United States. As of June 30, 2015, company employed 483 scientists in research and development functions.Highlights:1. Alkem Labs is 5th largest pharmaceutical company in India in terms of domestic sales.2. Alkem Labs products are also sold in 56 countries. In the United States, company has filed 66 abbreviated new drug applications.3. Company sells a range of high-quality, cost effective generic drugs to major drug chains, pharmaceutical retailers, wholesalers, food and grocery stores, distributors and managed care companies in the United States.
Objects of the Issue
Alkem Laboratories Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and
2
2. For the sale of 12,853,442 Equity Shares by the Selling Shareholders.
Shareholding & Lock-in
Pre-IPO Promoter Holding
11,95,65,000 shares
Post-IPO Promoter Holding
11,95,65,000 shares